On March 11, 2010, Jarvis, Ashley; Allerston, Charles K.; Jia, Haiyan; Herzog, Birger; Garza-Garcia, Acely; Winfield, Natalie; Ellard, Katie; Aqil, Rehan; Lynch, Rosemary; Chapman, Chris; Hartzoulakis, Basil; Nally, James; Stewart, Mark; Cheng, Lili; Menon, Malini; Tickner, Michelle; Djordjevic, Snezana; Driscoll, Paul C.; Zachary, Ian; Selwood, David L. published an article.Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the article was Small Molecule Inhibitors of the Neuropilin-1 Vascular Endothelial Growth Factor A (VEGF-A) Interaction. And the article contained the following:
We report the mol. design and synthesis of EG00229, 2, the first small mol. ligand for the VEGF-A receptor neuropilin 1 (NRP1) and the structural characterization of NRP1-ligand complexes by NMR spectroscopy and X-ray crystallog. Mutagenesis studies localized VEGF-A binding in the NRP1 b1 domain and a peptide fragment of VEGF-A was shown to bind at the same site by NMR, providing the basis for small mol. design. Compound 2 demonstrated inhibition of VEGF-A binding to NRP1 and attenuated VEGFR2 phosphorylation in endothelial cells. Inhibition of migration of endothelial cells was also observed The viability of A549 lung carcinoma cells was reduced by 2, and it increased the potency of the cytotoxic agents paclitaxel and 5-fluorouracil when given in combination. These studies provide the basis for design of specific small mol. inhibitors of ligand binding to NRP1. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate
The Article related to neuropilin vegf inhibitor design antitumor combination chemotherapy, Pharmacology: Structure-Activity and other aspects.Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics